The TyG index keeps appearing as a stratifier in diabetes cohorts — it is one of the subgroups in today's CGM study — and it costs nothing to calculate. It is derived from fasting triglycerides and fasting plasma glucose, both of which are on a routine panel: ln[fasting triglycerides (mg/dL) x fasting glucose (mg/dL) / 2].
Its value in clinic is as a surrogate marker of insulin resistance that does not need a fasting insulin assay, which many Indian laboratories do not run reliably or cheaply. It is a research-grade stratifier rather than a diagnostic threshold, and there is no single cut-off that carries across populations, so treat it as a way of ranking patients within your own practice rather than a number to act on in isolation.
Where it earns its place is in the patient whose HbA1c looks adequate but whose lipids, waist and blood pressure suggest the metabolic picture is worse than the glycaemia implies.
- Calculate from the fasting lipid profile and fasting glucose already in the chart — no additional test, no additional cost
- Use it to rank patients within your practice, not against a published cut-off from another population
- It needs a genuinely fasting sample; a random triglyceride makes it meaningless
- Treat it as a pointer towards insulin resistance, not as a diagnosis of it
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free